Bayer’s Nubeqa combination recommended by NICE to treat metastatic prostate cancer

PM Live

22 May 2023 - More than 47,000 new cases of prostate cancer are diagnosed every year in England.

Bayer’s Nubeqa (darolutamide) has been recommended by NICE as part of a combination treatment for patients with metastatic hormone-sensitive prostate cancer.

The final draft guidance from NICE specifically recommends Nubeqa tablets in combination with androgen deprivation therapy and docetaxel.

Read PM Live article

Michael Wonder

Posted by:

Michael Wonder